



## **Laurent Levy, pioneer in nanomedicine, elected Vice-Chairman of the European Technology Platform on Nanomedicine, representing European SMEs in the Executive Board**

### **ETPN has restructured its Executive Board to bring nanomedicine to the next level and to overcome the new challenges**

Paris, France, December 05, 2012 - Nanobiotix (Euronext: NANO / ISIN: FR0011341205), announced today that Laurent Levy, CEO of Nanobiotix, has been elected as Vice-Chairman of the European Technology Platform on Nanomedicine (ETPN) for two years. ETPN is a European association dedicated to structuring and developing the nanomedicine field. As one of the most mature associations in this field, ETPN is playing a major role for public and private entities. Laurent Levy is engaged to make nanomedicine a crucial public stake and bring Small and Medium sized Enterprises (SMEs) to the forefront of this area.

Nanomedicine is one of the key enabling technologies in the field of Life Sciences, already providing people with groundbreaking therapeutic and diagnostic solutions. Nanomedicine is also opening new ways to treat patients by providing new types of medicines.

The ETPN is an initiative led by industry and set up together with the European Commission to address the application of nanotechnology to achieve breakthroughs in healthcare. Laurent Levy will be responsible of SMEs' integration in the ETPN program in order to assist them to transfer their technologies faster and more efficiently to the patients and to the market.

#### ***An entrepreneur voice in strategic and growing industry in Europe***

There is an important need for efficient translation from discovery to development and commercialization. This requires the nanomedicine field to be well structured in order to build an ecosystem with sustainable business based on innovation.

*"My conviction is to foster the ecosystem of innovative SMEs and key stakeholders in nanomedicine. ETPN's main goal is to raise public awareness and to drive public decision makers towards strategic investment in this field. A significant part of the innovation in Nanomedicine is generated by SMEs and we need to efficiently transform those innovations into products for patients. Europe is already playing a key role in those technologies but we need to structure the industrial transition to create new jobs and be competitive based on new nanomedicine products",* says Laurent Levy.

The new members of the ETPN Executive Board, Laurent Levy, Michael Kuhn (Philips Healthcare) together with Patrick Boisseau (CEA-LETI) who was elected as the new Chairman, will work closely together, building upon their academic, industrial and business experiences.

The ETPN will establish new tools like a translation committee composed of nanomedicine entrepreneurs, academic and industrial advisors to help SMEs overcoming the gap between research and the clinical proof of concept.

**ABOUT ETP Nanomedicine - [www.etp-nanomedicine.eu](http://www.etp-nanomedicine.eu)**

The European Technology Platform Nanomedicine was established in 2005 as a joint venture of the European Commission and CEOs of large industrial companies such as Philips, Siemens and UCB, SMEs and academic research institutions to investigate and advance joint activities in the area of nanotechnology in medicine. Since 2005 the ETPN published a number of strategic documents outlining the needs and roadmaps for nanomedicine research in Europe. The ETPN contributed to set up numerous European funded projects providing a first impression of the conditions for a suitable social and economic environment and the structural requirements for an efficient translation of R&D results into innovative nanomedicine. The ETPN supports its members in coordinating their joint research efforts and improving communication amongst the members as well as towards the European Commission and the European Member States.

**About NANOBIOTIX – [www.nanobiotix.com](http://www.nanobiotix.com)**

Nanobiotix, pioneer and leader in nanomedicine, has developed a revolutionary concept dedicated to the local treatment of cancer. Nanobiotix is focused on the development of NanoXray, a pipeline of patented products, which are based on the physical mechanism of action of the nanoparticles interacting with X-rays and maximizing radiation effect into tumor cells. NanoXray products enhance the efficacy of the radiotherapy in the tumor without increasing healthy tissues damages. NanoXray products can be used with existing standard radiation equipments available in almost every hospital world-wide.

Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo that was incorporated in 2003 and has been primarily funded by leading European venture capital firms. The company has more than 30 employees and is based in Paris, France. Nanobiotix' objective is to enhance its leading position in the nanomedicine field on the main oncology markets. Its pipeline of universal products enable to target the major indications of cancers (breast cancer, prostate cancer, lung cancer...), leading to a potential market of several billion dollars. Thanks to the physical based mechanism of action of its nanoparticles, Nanobiotix brings out a unique business model with much lower risk than classic drug development, enabling a faster and less expensive time to market.

Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN Code: FR0011341205, Euronext mnemonic code: NANO, Bloomberg code: NANO:FP).

**Contact / Press Contact**

**Nanobiotix**

**Laurent Levy**

*CEO*

+33 (0)1 40 26 04 70

[laurent.levy@nanobiotix.com](mailto:laurent.levy@nanobiotix.com)

**NewCap.**

Financial communication  
and investors relations

**Louis-Victor Delouvrier /**

**Emmanuel Huynh**

+33 (0)1 44 71 98 53

[lvdelouvrier@newcap.fr](mailto:lvdelouvrier@newcap.fr)

**Yucatan**

Media relations

**Annie-Florence Loyer/**

**Nadège Le Lezec**

+33 (0)1 53 63 27 27 /

+33 (0)6 88 20 35 59

[afloyer@yucatan.fr](mailto:afloyer@yucatan.fr)

**DISCLAIMER**

This press release and the information it contains do not constitute an offer to sell or subscribe for, or a solicitation to purchase or subscribe for, Nanobiotix shares in any country. This press release contains forward-looking statements that relate to Nanobiotix' objectives based on the current expectations and assumptions of the company's management only and involve risk and uncertainties that could cause Nanobiotix to fail to achieve the objectives expressed by said forward-looking statements.